
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is attractive because it is successfully shifting from a generics-heavy model toward a higher-margin branded and innovative portfolio, with 3Q26 revenue of $4.395B, non-GAAP EPS of $0.86, and gross margin rising to 55.5% from 51.4% a year earlier. Its core franchises are showing durable momentum, as Austedo, Ajovy, and Uzedy are either growing or stabilizing, while biosimilars are strengthening replenishment and management expects adjusted EBITDA of $4.23B to $4.43B in FY26. The outlook is further supported by a deep immunology and neuroscience pipeline, including Weltruza and ecopipam, which should extend growth into 2028 and improve operating leverage as R&D spending and commercial investment translate into future launches.
Bears say
Teva Pharmaceutical Indus is viewed negatively because its core growth drivers appear fragile: AUSTEDO sales must exceed guidance, maintain share through 2029, and avoid earlier generic erosion, while the Olanzapine LAI launch depends on a favorable PDSS-free label and strong uptake. Its innovation thesis also looks exposed, since duvakitug must succeed in Phase 3 against Merck or Roche, and the company still needs to double biosimilar revenue by 2027 while reversing generic weakness after the Revlimid headwind. Beyond operating risk, material opioid, price-fixing, and environmental contingencies could pressure cash flow and de-levering, making the overall earnings and margin profile less dependable.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Teva Pharmaceutical (TEVA) Forecast
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares